Response's troponin I and CK-MB POC heart tests:
This article was originally published in Clinica
Executive Summary
Response Biomedical has received market clearance from Health Canada's Therapeutic Products Directorate to add two additional cardiac marker tests to its fluorescence-based, POC RAMP reader. The tests, for troponin I and CK-MB, are designed to help speed up heart attack diagnosis. The Vancouver, British Columbia firm has already gained Canadian approval to test for a third cardiac marker - myoglobin - on the RAMP reader and for the general clinical use of reader. The Reader and all three cardiac marker tests are already approved in the US, where, according to Response, the market for POC cardiac marker tests in 2004 is estimated to be around $150m.